WU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.